Truist Raises Its Price Target on BridgeBio Pharma, Inc. (BBIO) to $95 and Maintains a Buy Rating

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is among the 10 Fastest Growing NASDAQ Stocks to Buy.

On February 25, 2026, Truist analyst Danielle Brill raised the firm’s price target on BridgeBio Pharma, Inc. (NASDAQ:BBIO) to $95 from $86 and maintained a Buy rating on the shares. The analyst noted that the company had pre-announced Q4 Attruby sales of $146M in January, representing a 35% increase from Q3 and exceeding quarterly estimates. The performance was driven by an acceleration in the pace of new patient additions, which the analyst said appears to be continuing.

Also on February 25, 2026, Morgan Stanley analyst Sean Laaman raised the firm’s price target on BridgeBio Pharma, Inc. (NASDAQ:BBIO) to $98 from $96 and reiterated an Overweight rating after updating estimates following the company’s Q4 report.

On February 24, 2026, BridgeBio Pharma, Inc. (NASDAQ:BBIO) reported Q4 EPS of ($1.00), compared with consensus estimates of (67c). The company reported Q4 revenue of $154.18M, above the $149.07M consensus estimate. Co-Founder and CEO Neil Kumar said the company is reflecting on its progress over the past decade, highlighting three successful Phase 3 readouts delivered within a little over three months. Kumar said the results demonstrate the rigor of the company’s science and expressed hope that the progress could lead to six approved products as the company closes its first decade.

BridgeBio Pharma, Inc. (NASDAQ:BBIO) discovers, develops, and delivers medicines for patients with genetic diseases.

While we acknowledge the potential of BBIO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Tech Stocks that Beat Earnings Estimates and 40 Most Popular Stocks Among Hedge Funds Heading Into 2026

Disclosure: None.